India, July 1 -- image credit- freepik

Sun Pharma's purchase of Organon shows that leading Indian pharma companies are now focussed on owning therapeutic franchises instead of just selling generics in large volumes. The goal has clearly moved from "manufacture for the world" to "own the global value chain."

While Indian pharmaceutical companies are already recognised as some of the world's largest suppliers of medicines by volume, the transaction represents a pivotal shift in the industry's evolution. It signals India's transition beyond its traditional role as a global generics powerhouse toward becoming a diversified pharmaceutical leader with broad product portfolios, direct commercial presence in key international markets, and a str...